First-in-class drug approvals vs Cardiometabolic RNA and next-generation lipid drug trial starts in China

In 2025, first-in-class drug approvals in China stood at 11, against 12 for cardiometabolic RNA and next-generation lipid drug trial starts.

Change the pair

The series

Over time

China, spaced by time. Both series are in count, so they share one axis; the legend names each line.

First-in-class drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts

Unit: count · 10 observations

2 series · one axis

View the underlying data

First-in-class drug approvals and Cardiometabolic RNA and next-generation lipid drug trial starts: China
Indicator	Period	Type	Value
First-in-class drug approvals	2025	Actual	11
First-in-class drug approvals	2024	Actual	48
First-in-class drug approvals	2023	Actual	40
First-in-class drug approvals	2022	Actual	21
Cardiometabolic RNA and next-generation lipid drug trial starts	2025	Actual	12
Cardiometabolic RNA and next-generation lipid drug trial starts	2024	Actual	12
Cardiometabolic RNA and next-generation lipid drug trial starts	2023	Actual	7
Cardiometabolic RNA and next-generation lipid drug trial starts	2022	Actual	3
Cardiometabolic RNA and next-generation lipid drug trial starts	2021	Actual	4
Cardiometabolic RNA and next-generation lipid drug trial starts	2020	Actual	0

Source: NMPA, NHSA, ClinicalTrials.gov · CC BY 4.0 · First-in-class drug approvals · Cardiometabolic RNA and next-generation lipid drug trial starts

Shared periods

Side by side

4 periods are published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period	First-in-class drug approvals	Cardiometabolic RNA and next-generation lipid drug trial starts
2022	21 NMPA	3 ClinicalTrials.gov
2023	40 NMPA	7 ClinicalTrials.gov
2024	48 NMPA	12 ClinicalTrials.gov
2025	11 NHSA	12 ClinicalTrials.gov

Provenance

Where these numbers come from